SAN DIEGO, Sept. 10 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Rodman & Renshaw Annual Global Investment Conference. The details are as follows:
Date: September 14, 2010
Time: 5:45pm (EDT)
Location: New York Palace Hotel
Speaker: Mark Booth, Chief Commercial Officer
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved